{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T13:39:13Z","timestamp":1773063553907,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:00:00Z","timestamp":1668384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:00:00Z","timestamp":1668384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Data on safety and immunity elicited by a third booster dose of inactivated COVID-19 vaccine in children and adolescents are scarce. Here we conducted a study based on a double-blind, randomised, placebo-controlled phase 2 clinical trial (NCT04551547) to assess the safety and immunogenicity of a third dose of CoronaVac. In this study, 384 participants in the vaccine group were assigned to two cohorts. One received the third dose at a 10-months interval (cohort 1) and the other one at a 12-months interval (cohort 2). The primary endpoint is safety and immunogenicity following a third dose of CoronaVac. The secondary endpoint is antibody persistence following the primary two-dose schedule. Severities of local and systemic adverse reactions reported within 28 days after dose 3 were mild and moderate in both cohorts. A third dose of CoronaVac increased GMTs to 681.0 (95%CI: 545.2\u2013850.7) in cohort 1 and 745.2 (95%CI: 577.0\u2013962.3) in cohort 2. Seropositivity rates against the prototype were 100% on day 28 after dose 3. Seropositivity rates against the Omicron variant were 90.6% (cohort 1) and 91.5% (cohort 2). A homologous booster dose of CoronaVac is safe and induces a significant neutralising antibody levels increase in children and adolescents.<\/jats:p>","DOI":"10.1038\/s41467-022-34280-y","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T22:08:01Z","timestamp":1668463681000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Safety and immunogenicity following a homologous booster dose of CoronaVac in children and adolescents"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8902-3262","authenticated-orcid":false,"given":"Lei","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiwei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhifang","family":"Ying","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6830-5658","authenticated-orcid":false,"given":"Minjie","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuansheng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qun","family":"Shu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huixian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hengming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbin","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2571-4320","authenticated-orcid":false,"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2160-8870","authenticated-orcid":false,"given":"Yuliang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6825-3440","authenticated-orcid":false,"given":"Qiang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,14]]},"reference":[{"key":"34280_CR1","unstructured":"World Health Organization. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. https:\/\/www.who.int\/news\/item\/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern (2021)."},{"key":"34280_CR2","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41586-022-04411-y","volume":"603","author":"R Viana","year":"2022","unstructured":"Viana, R. et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature 603, 679\u2013686 (2022).","journal-title":"Nature"},{"key":"34280_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/22221751.2021.2017757","volume":"11","author":"L Zhang","year":"2022","unstructured":"Zhang, L. et al. The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron. Emerg. Microbes Infect. 11, 1\u20135 (2022).","journal-title":"Emerg. Microbes Infect."},{"key":"34280_CR4","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1056\/NEJMc2119236","volume":"386","author":"A R\u00f6ssler","year":"2022","unstructured":"R\u00f6ssler, A., Riepler, L., Bante, D., von Laer, D. & Kimpel, J. SARS-CoV-2 Omicron variant neutralization in serum from vaccinated and convalescent persons. N. Engl. J. Med. 386, 698\u2013700 (2022).","journal-title":"N. Engl. J. Med."},{"key":"34280_CR5","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S1473-3099(22)00129-3","volume":"22","author":"DJ Sheward","year":"2022","unstructured":"Sheward, D. J. et al. Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study. Lancet Infect. Dis. 22, 813\u2013820 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"34280_CR6","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41586-022-04399-5","volume":"602","author":"JM Carre\u00f1o","year":"2022","unstructured":"Carre\u00f1o, J. M. et al. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature 602, 682\u2013688 (2022).","journal-title":"Nature"},{"key":"34280_CR7","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41586-021-04387-1","volume":"602","author":"S Cele","year":"2022","unstructured":"Cele, S. et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature 602, 654\u2013656 (2022).","journal-title":"Nature"},{"key":"34280_CR8","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","volume":"602","author":"Y Cao","year":"2022","unstructured":"Cao, Y. et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 602, 657\u2013663 (2022).","journal-title":"Nature"},{"key":"34280_CR9","unstructured":"UK Health Security Agency. COVID-19 vaccine weekly surveillance reports (weeks 39 to 14, 2021 to 2022). https:\/\/www.gov.uk\/government\/publications\/covid-19-vaccine-weekly-surveillance-reports (2022)."},{"key":"34280_CR10","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/S1473-3099(22)00345-0","volume":"22","author":"ME McMenamin","year":"2022","unstructured":"McMenamin, M. E. et al. Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study. Lancet Infect. Dis. 22, 1435\u20131443 (2022).","journal-title":"Lancet Infect. Dis"},{"key":"34280_CR11","doi-asserted-by":"publisher","first-page":"0142322","DOI":"10.1128\/mbio.01423-22","volume":"13","author":"BM Schultz","year":"2022","unstructured":"Schultz, B. M. et al. A booster dose of coronavac increases neutralizing antibodies and T cells that recognize Delta and Omicron variants of concern. mBio\u00a013, 0142322 (2022).","journal-title":"mBio"},{"key":"34280_CR12","doi-asserted-by":"crossref","unstructured":"Yu X, et al. Three doses of an inactivation-based COVID-19 vaccine induces cross-neutralizing immunity against the SARS CoV-2 Omicron variant. Emerg. Microbes Infect. 11, 749\u2013752 (2022).","DOI":"10.1080\/22221751.2022.2044271"},{"key":"34280_CR13","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S1473-3099(20)30987-7","volume":"21","author":"Z Wu","year":"2021","unstructured":"Wu, Z. et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial. Lancet Infect. Dis. 21, 803\u2013812 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"34280_CR14","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1016\/S1473-3099(21)00319-4","volume":"21","author":"B Han","year":"2021","unstructured":"Han, B. et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1\/2 clinical trial. Lancet Infect. Dis. 21, 1645\u20131653 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"34280_CR15","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1473-3099(20)30843-4","volume":"21","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18\u201359 years: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial. Lancet Infect. Dis. 21, 181\u2013192 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"34280_CR16","unstructured":"Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes Moderna, Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-moderna-pfizer-biontech-bivalent-covid-19-vaccines-use (2022)."},{"key":"34280_CR17","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S1473-3099(21)00681-2","volume":"22","author":"G Zeng","year":"2022","unstructured":"Zeng, G. et al. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infect. Dis. 22, 483\u2013495 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"34280_CR18","unstructured":"National Health Commission of the People\u2019s Republic of China. Literal record of news conference on June 11, 2021 from Joint prevention and control mechanism of the State Council. http:\/\/www.nhc.gov.cn\/xcs\/s3574\/202106\/e28487f08ad745c5952356e448a87f13.shtml (2021)."},{"key":"34280_CR19","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1056\/NEJMc2103916","volume":"384","author":"N Doria-Rose","year":"2021","unstructured":"Doria-Rose, N. et al. Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19. N. Engl. J. Med. 384, 2259\u20132261 (2021).","journal-title":"N. Engl. J. Med."},{"key":"34280_CR20","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1056\/NEJMoa2114583","volume":"385","author":"EG Levin","year":"2021","unstructured":"Levin, E. G. et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N. Engl. J. Med. 385, e84 (2021).","journal-title":"N. Engl. J. Med."},{"key":"34280_CR21","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.cell.2022.01.019","volume":"185","author":"Z Cui","year":"2022","unstructured":"Cui, Z. et al. Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron. Cell 185, 860\u2013871.e13 (2022).","journal-title":"Cell"},{"key":"34280_CR22","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41586-021-04389-z","volume":"602","author":"D Planas","year":"2022","unstructured":"Planas, D. et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature 602, 671\u2013675 (2022).","journal-title":"Nature"},{"key":"34280_CR23","doi-asserted-by":"crossref","unstructured":"Mallory, R. M. et al. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial. Lancet Infect. Dis. 22, (2022).","DOI":"10.1101\/2021.12.23.21267374"},{"key":"34280_CR24","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/s41422-022-00677-z","volume":"32","author":"L Wang","year":"2022","unstructured":"Wang, L. et al. Selection and structural bases of potent broadly neutralizing antibodies from 3-dose vaccinees that are highly effective against diverse SARS-CoV-2 variants, including Omicron sublineages. Cell Res. 32, 691\u2013694 (2022).","journal-title":"Cell Res"},{"key":"34280_CR25","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1126\/science.abn7591","volume":"375","author":"A Muik","year":"2022","unstructured":"Muik, A. et al. Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera. Science 375, 678\u2013680 (2022).","journal-title":"Science"},{"key":"34280_CR26","doi-asserted-by":"crossref","unstructured":"Cheng, S. M. et al. SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022. Euro Surveill. 27, 2200178 (2022).","DOI":"10.2807\/1560-7917.ES.2022.27.18.2200178"},{"key":"34280_CR27","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.cell.2021.12.002","volume":"185","author":"M Gagne","year":"2022","unstructured":"Gagne, M. et al. Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung. Cell 185, 113\u2013130.e15 (2022).","journal-title":"Cell"},{"key":"34280_CR28","doi-asserted-by":"crossref","unstructured":"Zhang, J. et al. Differential antibody response to inactivated COVID-19 vaccines in healthy subjects. Front. Cell Infect. Microbiol. 11, 791660 (2021).","DOI":"10.3389\/fcimb.2021.791660"},{"key":"34280_CR29","doi-asserted-by":"crossref","unstructured":"Dan, J. M. et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 371, eabf4063 (2021).","DOI":"10.1126\/science.abf4063"},{"key":"34280_CR30","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1038\/s41423-021-00730-8","volume":"18","author":"Y Deng","year":"2021","unstructured":"Deng, Y., Li, Y., Yang, R. & Tan, W. SARS-CoV-2-specific T cell immunity to structural proteins in inactivated COVID-19 vaccine recipients. Cell Mol. Immunol. 18, 2040\u20132041 (2021).","journal-title":"Cell Mol. Immunol."},{"key":"34280_CR31","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.immuni.2021.01.014","volume":"54","author":"I Quast","year":"2021","unstructured":"Quast, I. & Tarlinton, D. B cell memory: understanding COVID-19. Immunity 54, 205\u2013210 (2021).","journal-title":"Immunity"},{"key":"34280_CR32","unstructured":"National Medical Products Administration. Guidelines for grading standards of adverse events in clinical trials of preventive vaccines. https:\/\/www.nmpa.gov.cn\/xxgk\/ggtg\/qtggtg\/20191231111901460.html (2019)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-34280-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-34280-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-34280-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T22:11:22Z","timestamp":1668463882000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-34280-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,14]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["34280"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-34280-y","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,14]]},"assertion":[{"value":"5 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6952"}}